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www.cdatm.orgAbstractObjective: To investigate the correlation between serum Omentin-1 levels and the presence of osteoporosis in older men.
Methods: Serum Omentin-1, bone turnover biochemical markers, and bone mineral density (BMD) were determined in 45 older
men with osteoporosis or 45 older men without osteoporosis (65e70 years old).
Results: Omentin-1 levels were increased in older men with osteoporosis, and the differences remained significant after con-
trolling for fat mass. Omentin-1 was negatively correlated with BMD. In a multiple linear stepwise regression analysis, Omentin-1,
lean mass, but not fat mass, were independent predictors of BMD for the combined group. Significant negative correlations between
Omentin-1 and bone-specific alkaline phosphatase (BAP) and bone cross-linked N-telopeptides of type Ⅰ collagen (NTX) were
found. Omentin-1 was also independently associated with BMD and bone turnover markers in older men with osteoporosis and
control groups that were considered separately.
Conclusions: Omentin-1 is an independent predictor of BMD in older men with osteoporosis, and it is negatively correlated with
bone turnover biochemical markers. It is suggested that Omentin-1 may exert a negative effect on bone mass through the regulation
of the osteoblast differentiation in the older men with osteoporosis.
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Osteoporosis, is a metabolic bone disease, charac-
terized by low bone mass and microarchitectural dete-
rioration of bone tissue.1 Compared with osteoporosis in
post-menopause, osteoporosis in older men has higher
risks of fracture and fatality.2,3 But the mechanism re-
mains unclear. Although the relationship between lean
mass and bone mineral density (BMD) is well known,4,5
the relationship between fat-dependent factors andElsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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various factors like sex, genetics, and regional risk
factors.
Fat mass plays an important role in bone meta-
bolism. It has been demonstrated that certain adipo-
kines, such as leptin, adiponectin and Omentin-1, can
modulate bone metabolism in vitro and in vivo.6e11
Adiponectin has been found to be related to the
decreased BMD in older men.12
Omentin-1 (also intelectin-1) is a novel visceral
adipose tissue-derived cytokine. The level of circu-
lating Omentin-1 is high in plasma and is decreased in
patients with obesity and increased after weight loss. It
correlates positively with adiponectin and negatively
with body mass index (BMI) and the leptin level.13,14
Omentin-1 has been reported to inhibit osteoblast dif-
ferentiation in vitro.15,16 In co-culture systems of os-
teoblasts and osteoclast precursors, Omentin-1 reduced
osteoclast formation by stimulating osteoprotegerin
(OPG) and inhibiting the receptor activator for nuclear
factor kB ligand (RANKL) production in osteoblasts.
This suggested that Omentin-1 may play a pivotal role
in the dynamic balance of bone formation and bone
resorption.
The present study was undertaken to investigate
whether Omentin-1 levels were associated with BMD
and bone turnover biochemical markers in older men
with osteoporosis. Serum Omentin-1, adiponectin,
leptin and 25-hydroxyvitamin D and the bone turnover
markers such as BAP and NTX were measured to
investigate the relationship of these factors and BMD
in older men with osteoporosis.
Methods
Subjects
We enrolled 45 older men with osteoporosis who met
the World Health Organization (WHO) criteria for
osteoporosis and 45 older men without osteoporosis
were enrolled as controls. The older men with osteopo-
rosis and controls were recruited from the patients in
Hunan Province Geriatric Hospital during 2012 and
2013 in Changsha (China). The patients who had sec-
ondary osteoporosis diseases or who had previously
taken any special medicine which could affect bone
metabolism, such as glucocorticoids, or any treatment
for osteoporosis were excluded from the study. Any
patients with severe heart, brain and kidney diseases
were not included in the study.
All subjects were screened through a detailed ques-
tionnaire, medical history and physical examination.Information on dietary intake through a food frequency
questionnaire, as well as habitual physical activity were
recorded. Body height andweight weremeasured using a
stadiometer and a standardized balance-beam scale,
respectively.
This study was approval by the South China Uni-
versity Research Ethics Committee, and all subjects and
their family gave their informed consent to participate.
BMD measurements and body composition measurements
BMD was measured by dual energy X-ray absorp-
tiometry (DXA) using a Lunar device (Lunar, MA,
USA) as previously described.17e19 Supine position
with the hip and knee fixed in flexion immobilization
by means of supports were standard positions for the
measurement. Total body, lumbar spine L2-L4, and
total hip BMD were expressed in g/cm2. Body fat mass
and lean body mass were measured using DXA.
The precision of the DXA was evaluated over three
repeated measurements of different BMD values in 75
subjects, and gave a mean coefficient of variation (CV)
for all regions of 0.58 ± 0.20% (mean ± SD; range:
0.40e1.00%). A control spine phantom scan was per-
formed everyday with a long-term (more than nine
years) CV of 0.30e0.41% and the root-mean-square
coefficient of variation was 0.37% (degrees of freedom
(df) ¼ 1576).19
Serum Omentin-1, adiponectin, leptin measurement
Blood samples were collected between 7:00 A.M.
and 9:00 A.M. after fasting overnight and the samples
were allowed to clot. Thereafter, the samples were
centrifuged and divided into aliquots and stored at
70 C until assayed. The levels of Omentin-1 in human
serum were determined using an Omentin-1 enzyme-
linked immunosorbent assay (ELISA) kit (Phoenix
Pharmaceuticals, Inc., Belmont, CA, USA). The levels
of adiponectin in human serum were determined using
an adiponectin ELISA kit (Phoenix Pharmaceuticals,
Inc.). Serum leptin was detected using an ELISA kit
(Phoenix Pharmaceuticals). The intra- and inter-assay
coefficients of variation were 5.0% and 6.0% for
Omentin-1, 5.6% and 7.0% for adiponectin, and 6.0%
and 7.1% for leptin.
Hormone assays
The serum estradiol level was determined with
a competitive immunoassay that uses direct
chemiluminescence (Automated Chemiluminescence
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LLC Diagnostics, Tarrytown, NY, USA). The
25-hydroxyvitamin D was measured with an ELISA kit
(BiomedicaMedizinprodukte GmbH&CoKG, Vienna,
Austria). The intra- and inter-assay CVs were 6.0%
and 6.7% for estradiol and 5.2% and 7.1% for
25-hydroxyvitamin D respectively.
Bone turnover biochemical markers measurement
The serum concentration of bone alkaline phos-
phatase (BAP) as the marker of bone formation were
measured with an ELISA kit (BAP from MetraTM BAP
EIA kit, Quidel Corporation, USA). As a marker of
bone resorption, serum cross-linked N-telopeptides of
type Ⅰ collagen (NTX) were measured using an ELISA
kit (Osteomark, Ostex, Inc., Seattle, WA, USA). TheTable 1
Subject characteristics, and bone and biochemical parameters of 45
older men with osteoporosis and 45 control group men (n ¼ 90).
Items OP (n ¼ 45) Control
(n ¼ 45)
P
Age, years 66.35 ± 0.83 66.28 ± 0.79 NS
BMI, kg/cm2 20.33 ± 0.54 20.99 ± 0.68 NS
Fat mass (kg) 9.27 ± 0.64 8.67 ± 0.64 <0.001
Lean mass (kg) 32.31 ± 0.64 32.26 ± 1.46 NS
LS BMD (g/cm2) 0.802 ± 0.049 0.973 ± 0.040 <0.001
Hip BMD (g/cm2) 0.821 ± 0.040 0.942 ± 0.041 <0.001
T-BMD (g/cm2) 0.831 ± 0.049 1.041 ± 0.049 <0.001
BAP (mg/ml) 30.16 ± 3.09 34.90 ± 2.73 <0.001
NTX (nmol/BCE) 28.11 ± 2.50 31.78 ± 2.90 <0.001
Omentin-1 (ng/ml) 263.93 ± 22.88 183.91 ± 22.91 <0.001
Adiponectin (mg/ml) 10.50 ± 1.13 10.90 ± 0.74 <0.001
Leptin (ng/ml) 7.89 ± 0.49 9.29 ± 0.95 <0.001
Estradio (pmol/L) 17.08 ± 0.82 19.16 ± 0.84 <0.001
25-hydroxyvitamin
(ng/ml)
32.83 ± 1.38 34.87 ± 1.59 <0.001
Values are presented as Mean ± SD. BMI: body mass index; BAP:
bone alkaline phosphatase; LS BMD : lumbar spine bone mineral
density; T-BMD: thoracic spine bone mineral density; NTX: Cross-
linked N-telopeptides of type I collagen; BMD: bone mineral den-
sity; OP:osteoporosis; NS: Not significant.
Table 2
Correlation coefficients of serum Omentin-1, adiponectin, leptin levels and
Items T-BMD LS BMD
Unadjusted Age and fat
mass adjusted
Unadjuste
Omentin-1 0.513** 0.497** 0.622**
Adiponectin 0.263* 0.291* 0.304*
Leptin 0.367** 0.338** 0.384**
BMD: bone mineral density; T-BMD: total BMD; LS BMD: lumbar spine
efficients after adjustment for age and fat mass in the group as a whole areintra- and inter-assay CVs were 5.1% and 7.0% for
BAP 5.3% and 7.9% for NTX, respectively.20
Statistical analysis
SPSS 17.0 was used for the statistical analyses. The
results were provided as mean and standard deviation
(Mean ± SD). The correlations between Omentin-1,
adiponectin, leptin and BMD, and bone turnover bio-
markers were made using Pearson's correlation analysis
and partial correlation analysis. Multivariate linear
stepwise analysis was performed to determine how
much of the variance in BMD at various skeletal regions
could be explained by age, BMI, fat mass, leanmass, 25-
hydroxyvitamin D, estradiol, serum Omentin-1, adipo-
nectin, and leptin.Results
Clinical characteristics of the study participants
The characteristics of the participant are summarized
in Table 1. Omentin-1 levels were significantly higher in
older men with osteoporosis subjects than controls.
Relationships between serum Omentin-1, adiponectin
and leptin levels and BMD
Table 2 showed that there were significant negative
correlations between Omentin-1 and BMD for the
total body, lumbar spine, and total hip determinations,
and they remained significant after adjustment for age
and fat mass. There were significant negative
relationships between adiponectin and BMD for the
total body, lumbar spine, and total hip determinations
that disappeared after adjustment for age and fat mass.
There existed significant positive relationships
between leptin and BMD for the total body,
lumbar spine, and total hip determinations thatBMD in the group as a whole (n ¼ 50).
Hip BMD
d Age and fat
mass adjusted
Unadjusted Age and fat
mass adjusted
0.601** 0.679** 0.636**
0.406* 0.323* 0.446*
0.352** 0.409** 0.388**
BMD; Pearson's correlation coefficients and Partial correlation co-
shown. **P < 0.01, *P < 0.05.
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mass.
Multiple regression analyses identified as predictors
of BMD
Regression modeling to eliminate confounding var-
iables was performed for the group as a whole and also
for the individual groups. The parameters identified as
significant and independent determinant factors of
BMD for the group as a whole are shown in Table 3 by a
multiple linear regression analysis. The dependent
variables were BMD of the total body, lumbar spine, and
total hip. Several independent variables were entered in
the regression analysis models, including age, BMI, fat
mass, lean mass, 25-hydroxyvitamin D, estradiol, serum
Omentin-1, adiponectin, and leptin. In the model with
total body BMD as the dependent variable, the signifi-
cant independent variables were Omentin-1, lean mass,
Vitamin D, BMI, and adiponectin, and these explained
25.6% of the total body BMD variance (R2 ¼ 0.256). In
the model with the lumbar spine BMD as the dependent
variable, the significant independent variables were
Omentin-1, lean mass, Vitamin D, and BMI, and these
explained 26.8% of the lumbar spine BMD variance
(R2 ¼ 0.268). In the model with total hip BMD as the
dependent variable, the significant independent vari-
ables were Omentin-1, lean mass, Vitamin D, and BMI,
and these explained 24.9% of the total hip BMD vari-
ance (R2 ¼ 0.249). These results show that Omentin-1,
lean mass, Vitamin D, BMI, and adiponectin are the
significant predictors for BMD.
In older men in the osteoporosis group, BMI,
Omentin-1, lean mass, and adiponectin were also sig-
nificant and independent determining factors. In the
model with total body BMD as the dependent variable,
the significantly independent variables were Omentin-
1, lean mass, BMI, and adiponectin and these
explained 4.6% of the total body BMD variance
(R2 ¼ 0.046). In the model with lumbar spine BMD as
the dependent variable, the significant independentTable 3
Parameters identified as significant and independent predictors of BMD in t
Parameters T-BMD (R2 ¼ 0.256) LS BMD
b-coefficient P b-coeffici
Omentin-1 0.189 0.000 0.124
BMI 0.328 0.000 0.209
Lean mass 0.523 0.000 0.466
VD 0.209 0.003 0.197
Adiponectin 0.115 0.010 0.136
Multiple regression analyses in the group as a whole (n ¼ 90); BMD: bonevariables were Omentin-1, lean mass, Vitamin D, BMI,
and adiponectin, and these explained 2.3% of the
lumbar spine BMD variance (R2 ¼ 0.023). In the
model with total hip BMD as the dependent variable,
the significant independent variables were Omentin-1,
lean mass, Vitamin D, and adiponectin and these
explained 0.9% of total hip BMD variance
(R2 ¼ 0.009).
In the healthy group, Omentin-1, Vitamin D and
lean mass were also significant and independent
determining factors. In the model with total body BMD
as the dependent variable, the significantly independent
variables were Omentin-1, lean mass, BMI and adi-
ponectin, and these explained 5.3% of total body BMD
variance (R2 ¼ 0.053). In the model with lumbar spine
BMD as the dependent variable, the significant inde-
pendent variables were Omentin-1, lean mass, BMI
and adiponectin, and these explained 2.0% lumbar
spine BMD variance (R2 ¼ 0.020). In the model with
total hip BMD as the dependent variable, the signifi-
cant independent variables were Omentin-1, lean mass,
BMI and adiponectin, and these explained 1.5% of
total hip BMD variance (R2 ¼ 0.015).
Association between serum Omentin-1 and bone
turnover biochemical markers
Serum BAP as a bone formation marker and serum
NTX as a bone resorption marker were assayed. In
both of the individual groups there was a significant
negative correlation between Omentin-1 and NTX,
BAP. The correlations were still significant after
adjustment for age and fat mass. The R values in the
whole group, in the older men with osteoporosis group,
and in the control group are shown in the Table 4.
Discussion
Older men with osteoporosis have low bone mineral
density (BMD). Recent studies have shown that cyto-
kines secreted by adipose tissue participate in bonehe group as a whole (n ¼ 90).
(R2 ¼ 0.268) Hip BMD (R2 ¼ 0.249)
ent P b-coefficient P
0.006 0.162 0.002
0.012 0.297 0.008
0.000 0.431 0.000
0.000 0.174 0.012
0.008 0.153 0.006
mineral density; BMI: body mass index; VD: 25-hydroxyvitamin D.
Table 4
Correlation coefficients of serum Omentin-1, BAP and NTX in the whole group, older men with osteoporosis and control groups.
Item BAP NTX
Unadjusted Age and fat mass adjusted Unadjusted Age and fat mass adjusted
Total 0.815* 0.734* 0.706* 0.698*
OP 0.553* 0.437* 0.402* 0.390*
Control 0.552* 0.621* 0.446* 0.470*
Pearson's correlation coefficients and Partial correlation coefficients after adjustment for age and fat mass in the three groups were shown; BAP:
bone alkaline phosphatase; NTX: Cross-linked N-telopeptides of type I collagen; OP:osteoporosis; *P < 0.05.
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between serum levels of ‘adipokines’ and BMD,
including biochemical bone turnover markers in older
men with osteoporosis. Our results showed that
Omentin-1 was significantly associated with BMD for
the total body, the lumbar spine, and the total hip in
older men with osteoporosis, and this association was
independent of age, fat mass, and other hormonal
factors. Moreover, Omentin-1 was negatively corre-
lated with BAP and NTX in both older men in the
osteoporosis group and those in the control group. Our
study showed that Omentin-1 correlated negatively
with markers of bone turnover in both older men with
osteoporosis and those in the control group. It sug-
gested that Omentin-1 played a role both in older men
with osteoporosis and those in the control group. But
the Omentin-1 level in older men with osteoporosis
was higher than in the men in the control group, which
indicated Omentin-1 might played a role in the
decreased BMD of older men with osteoporosis. This
finding suggested that Omentin-1 played a significant
role in regulating bone mass in older men with osteo-
porosis via suppressing bone formation.
In the simple correlation analysis, significant
negative correlations were found between Omentin-1
and BMD at various skeletal regions in the group as
a whole and also in the individual groups. Significant
predictors for BMD, as assessed by multivariate linear
regression analysis, were BMI, lean mass, and
Omentin-1, but not fat mass. These results showed that
Omentin-1 was an independent predictor of BMD in
older men with osteoporosis and that this was inde-
pendent of fat mass.
Fat mass was not the significant predictor for BMD,
suggesting that the effects of Omentin-1 on BMD were
independent of fat mass. This data was consistent with
recent reports fromothers showing that fatmasswas not a
determinant of BMD.22 Furthermore, the results showed
that Omentin-1 levels were negatively correlated with
NTXandBAPeven after adjustment for age and fatmass.
Thus, Omentin-1 may exert a negative effect on bonemass not by inhibiting bone resorption associated with
bone loss in older men with osteoporosis.
Omentin-1 participates in the regulation of bone
metabolism and its influence may be negative.
Recently, a study demonstrated that Omentin-1
inhibited osteoblastic differentiation in vitro.23
Omentin-1 also reduces osteoclast formation in co-
culture systems through stimulating OPG and inhibit-
ing RANKL production in osteoblasts via the PI3K/
Akt signaling pathway.15 RANKL promotes osteoclast
formation and activation, suppresses osteoclast
apoptosis, and OPG has been shown to directly block
all RANKL-mediated actions.24 In our research,
increased Omentin-1 levels were negatively correlated
with BMD and bone turnover markers in older
men with osteoporosis. Thus, it suggested Omentin-1
could be exerting its negative effect on bone meta-
bolism by inhibiting bone-formation in older men with
osteoporosis.
Combined with the previous research,15,16 our re-
sults suggested two distinct actions of Omentin-1 on
bone formation. One action was reducing osteoclast
formation indirectly through stimulating OPG and
inhibiting RANKL production in osteoblasts. The other
action was directly inhibiting osteoblast differentiation.
Compared with the control group, the bone turnover
marker levels in older men with osteoporosis were
lower, while Omentin-1 levels were higher. This in-
dicates that there is a suppressive effect of Omentin-1
on bone turnover and bone mass. Our present
observations showed that Omentin-1 exerts a negative
effect on BMD in older men with osteoporosis with
decreased bone turnover makers. Previous studies have
found that lean mass and some other factors were
greatly correlated with BMD,4 and this could explain
why these parameters were independent predictors of
BMD in older men with osteoporosis and controls. In
addition, our data showed that Omentin-1 was also an
independent predictor of BMD in healthy controls. It
indicated that high Omentin-1 levels were a negative
factor for BMD in the whole group. The level of
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older men without osteoporosis were enrolled as con-
trols), which might explain why the BMD level was
lower than that of healthy group. Thus, our data
showed that Omentin-1 might weaken more bone for-
mation than bone resorption, therefore decreasing bone
mass.
In the multiple linear regression analysis, adipo-
nectin showed a negative relationship with BMD and
was an independent determinant factor for BMD.
A previous study has reported that adiponectin was
independently associated with lumbar spine and
femoral neck-bone BMD.12 But our recent study found
that estrogen suppressed the effect of adiponectin on
bone metabolism via blocking the activation of
adiponectin-induced p38 MAPK.25 So, in older men
with osteoporosis, the decreased estrogen levels pro-
moted the action of adiponectin on bone mass.
Leptin was not a significant predictor for BMD in
our study. The relationship between serum leptin and
BMD was ambiguous. Previous study showed that
serum leptin was inversely associated with BMD,26
while other studies showed a positive correlation.27
Our data showed that leptin had a positive association
with BMD in the simple correlation, but this relation-
ship disappeared in the regression model. These
differing results may depend on the inverse functions of
leptin on BMD through binding at the ObRs receptor in
the central nervous system (CNS) and at various pe-
ripheral tissues.28 This showed complex interactions
between hormones and body composition in deter-
mining bone metabolism.
The serum 25(OH)VD was positively correlated
with the T score of the neck, ward, greater trochanter
of the femur and vertebrae lumbales.29 In our study,
25(OH)VD showed a positive relationship with the
lumbar spine and total hip BMD which coincides with
the previous finding. Therefore, a 25(OH)VD defi-
ciency may be an independent predictor for BMD.
In conclusion, the present study provided evidence
that Omentin-1, a novel visceral adipose tissue-derived
cytokine, was an independent predictor of BMD both
in older men with osteoporosis and control. And it
showed a negative correlation with bone turnover
markers. It suggested that Omentin-1 may exert a
negative effect on bone mass by inhibiting bone for-
mation in older men with osteoporosis.
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